|
Discontinued Operations (Discontinued Operations in the Company's Consolidated Statements of Operations and Comprehensive Loss) (Details) (USD $)
In Thousands, unless otherwise specified
|
3 Months Ended |
9 Months Ended |
|
Sep. 30, 2014
|
Dec. 31, 2013
|
Sep. 30, 2013
|
Sep. 30, 2014
|
Sep. 30, 2013
|
| Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |
|
|
|
|
|
| Restructuring charges |
|
|
|
|
$ (742) |
| Gain on disposal of assets |
0 |
|
|
1,149 |
|
| Net income (loss) from discontinued operations |
58 |
|
(1,337) |
1,195 |
(1,337) |
|
Tranzyme Pharma Inc. [Member]
|
|
|
|
|
|
| Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |
|
|
|
|
|
| Revenue |
0 |
|
167 |
0 |
167 |
| Research and development |
0 |
|
(503) |
0 |
(503) |
| General and administrative |
0 |
|
(168) |
0 |
(168) |
| Amortization of intangible assets |
0 |
|
(93) |
0 |
(93) |
| Restructuring charges |
0 |
(117) |
(742) |
0 |
(742) |
| Gain on disposal of assets |
0 |
|
0 |
1,149 |
0 |
| Settlement of certain restructuring charges |
68 |
|
0 |
68 |
0 |
| Other income (loss) from discontinued operations |
0 |
|
2 |
(6) |
2 |
| Recognition of accumulated translation adjustments upon deconsolidation of subsidiary |
(10) |
|
0 |
(16) |
0 |
| Net income (loss) from discontinued operations |
$ 58 |
|
$ (1,337) |
$ 1,195 |
$ (1,337) |